Natural Product (NP) Details

General Information of the NP (ID: NP9583)
Name
Paroxetine
Synonyms
paroxetine; 61869-08-7; Paxil; Paxil CR; Casbol; Seroxat; Paroxetina; Paroxetinum; Aropax; Paroxetinum [INN-Latin]; Paroxetina [INN-Spanish]; BRL 29060; Paxetil; FG 7051; Pexeva; Frosinor; Motivan; PaxPar; (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3s,4r)-3-((benzo[d][1,3]dioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; BRL-29060; UNII-41VRH5220H; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine; [3H]Paroxetine; FG-7051; CHEMBL490; (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S,4R)-; CHEBI:7936; 41VRH5220H; C19H20FNO3; 110429-35-1; DSSTox_CID_3425; (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine; (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine; Paroxetine (TN); DSSTox_RID_77022; Piperidine, 3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)-, (3S-trans)-; DSSTox_GSID_23425; Paroxetine [USAN:INN:BAN]; CHEMBL1708; Paroxetine Base; piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S,4R)-; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-,(3S,4R)-; (-)-Paroxetine; PAROXETINE HCL HEMIHYDRATE; CAS-61869-08-7; Paroxetine (USP/INN); 3h-paroxetine; Paroxetine.HCl; Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)-; NCGC00182968-01; 8PR; NNC-20-7051; Spectrum_001752; SpecPlus_000788; Prestwick3_000851; Spectrum5_001665; (-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine; SCHEMBL27799; BSPBio_000861; KBioSS_002232; BIDD:GT0673; DivK1c_006884; BPBio1_000949; GTPL4790; DTXSID3023425; BDBM22416; HSDB 7175; KBio1_001828; KBio2_002232; KBio2_004800; KBio2_007368; HMS2090H05; ZINC527386; Tox21_113123; BDBM50331515; (-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine; AKOS015888636; Tox21_113123_1; AC-8185; DB00715; SDCCGSBI-0051908.P003; (-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine; (3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine; NCGC00025355-02; NCGC00025355-03; NCGC00025355-04; NCGC00025355-05; NCGC00025355-06; NCGC00025355-07; NCGC00025355-08; NCGC00025355-09; NCGC00025355-12; NCGC00025355-22; SBI-0051908.P002; AB00514724; C07415; D02362; AB00053704-21; AB00053704_22; AB00053704_23; Paroxetine Hydrochloride Anhydrous EP Impurity E; 869P087; paroxetine hydrochloride (anhydrous or hemihydrate); Q408471; BRD-K37991163-003-02-7; BRD-K37991163-050-05-1; cis-Paroxetine; Paroxetine USP Related Compound D;[(3S,4R)-4-(p-Fluorophenyl)-3-piperidyl](1,3-dioxa-5-indanyloxy)methane
    Click to Show/Hide
Species Origin Areca catechu ...     Click to Show/Hide
Areca catechu
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Arecales
Family: Arecaceae
Genus: Areca
Species: Areca catechu
Disease Depression [ICD-11: 6A70-6A71] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -5.178
 
MDCK Permeability
 -4.929
 
PAMPA
 +
 
HIA
 - - -
 
Distribution
VDss
 1.178
 
PPB
 88.7%
 
BBB
 +++
 
Metabolism
CYP1A2 inhibitor
 +++
CYP1A2 substrate
 +++
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 +++
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - -
CYP2D6 substrate
 +++
CYP3A4 inhibitor
 +++
CYP3A4 substrate
 ++
CYP2B6 inhibitor
 +++
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - - -
 
Excretion
CLplasma
 5.045
 
T1/2
 0.603
Toxicity
DILI
 ++
 
Rat Oral Acute Toxicity
 ++
 
FDAMDD
 +
 
Respiratory
 +++
 
Human Hepatotoxicity
 ++
 
Ototoxicity
 +
 
Drug-induced Nephrotoxicity
 +++
 
Drug-induced Neurotoxicity
 +++
 
Hematotoxicity
 +
 
Genotoxicity
 ++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H20FNO3
PubChem CID
43815
Canonical SMILES
C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
InChI
1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
InChIKey
AHOUBRCZNHFOSL-YOEHRIQHSA-N
CAS Number
CAS 61869-08-7
ChEBI ID
CHEBI:7936
TTD Drug ID
D06GDY
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Everolimus      Renal cell carcinoma     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model SH-SY5Y CVCL_0019 Neuroblastoma Homo sapiens
                    Experimental
                    Result(s)		 Combination treatment with Everolimus and Paroxetine showed synergistic post-ischemic neuroprotective efficacy.
Target and Pathway
Target(s) Serotonin transporter (SERT)  Molecule Info  [3]
KEGG Pathway Serotonergic synapse Click to Show/Hide
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway 5HT1 type receptor mediated signaling pathway Click to Show/Hide
2 5HT2 type receptor mediated signaling pathway
3 5HT3 type receptor mediated signaling pathway
4 5HT4 type receptor mediated signaling pathway
WikiPathways Monoamine Transport Click to Show/Hide
2 SIDS Susceptibility Pathways
3 NRF2 pathway
4 Synaptic Vesicle Pathway
5 Serotonin Transporter Activity
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4790).
Reference 2 The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro. Cell Mol Neurobiol. 2018 Oct;38(7):1383-1397.
Reference 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link